UK markets closed

Heron Therapeutics, Inc. (HRTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
4.2200+0.2100 (+5.24%)
At close: 04:00PM EDT
4.1200 -0.10 (-2.37%)
After hours: 05:15PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • R
    Ray
    Notice how the negative posts increase when the stock price drops. Those are from shorters trying to push the stock down further. When you see them, label them as a shorter and give them a thumbs down. There are tons of them on this board. Was that an 11.69% increase today? Nice.
  • P
    Pioneer
    Just hold on to this one
  • T
    T
    Chart looks very good, a short squeeze is imminent imho.
  • P
    P
    20.7 million rescue treatments annually on PONV (pg 14 on slide deck) - that's a huge off-label opportunity for a 30 sec. IV push that works in less than 5 minutes - seems like the off label use will dwarf the labelled use of the drug.

    Whoever asked that question on the call about doing a study on APONVIE as a rescue treatment and Barry's response about a study probably wouldn't be needed (most would connect the dots and use it) was great.
  • H
    Hmmm
    Now that the approval for HTX-019 is behind them...can they get to Cash Flow Positive?
    Let's start plugging in some numbers.

    ................................................(50% QonQ).....(C+P+Z).......Run Rate
    Year.....Qtr...CINV........PONV.....Zynrelef....Total Sales...Annualized
    2022.....1.....22.40.........................1.10..........23.50.....
    2022.....2.....25.20.........................2.50..........27.70.....
    2022.....3.....23.00.........................3.75..........26.75.....
    2022.....4.....24.50..........5.00.........5.63..........35.13.....
    ----------------------------------------------------------------------------------
    Total 2022...95.10..........5.00........12.98........113.08.....
    ----------------------------------------------------------------------------------
    2023.....1.....24.64........11.00..........8.44.........44.08.....176.31
    2023.....2.....27.72........16.00.........12.66........56.38.....225.51
    2023.....3.....25.30........23.00.........18.98........67.28.....269.14
    2023.....4.....26.95........28.00.........28.48........83.43.....333.71
  • A
    A
    in the last 5 trading days, 50%-75% of the daily volume is short...They are 100% in charge of the direction...ugh!
  • C
    Carlos
    hope this is not a sell the news event
  • H
    Hmmm
    Current (2022) market for oral Aprepitant/Emend = 500,000 units (growing @ 100k+ units per year)
    2020 market for surgical high risk PONV = 14 M procedures (5 M get PONV despite prophylaxis) (a lot of room to expand the current Aprepitant/Emend PONV market)

    Launch of Cinvanti for first 2 years below...would think the APONVIE launch would be at a minimum a similar units sold launch:

    ........................... (in $ millions).....(in units ,000)
    Time Period....Cinvanti Sales..........Units Sold
    1Q 2018..................5.2............................22
    2Q 2018................11.2............................49
    3Q 2018................16.4............................85
    4Q 2018................23.4..........................124
    1Q 2019................28.0..........................158
    2Q 2019................33.2..........................174
    3Q 2019................36.4..........................194...47% of Emend CINV market
    4Q 2019................34.4..........................197...generic arbitrage begins
  • E
    EyeSee
    Really surprised we didn’t move up on approval announcement and haven’t broken 5 dollars. Bluebird dropped as well after approval announcement. Dropping on good news is wacky.
  • P
    PJ
    Trading halted. News coming!
  • H
    Hmmm
    If at the end of 2023 each category of drugs are doing $100 mil annual run rate (CINV / PONV / Post Op Pain)...that's $300 mil in sales. 127 mil shares x $4.65 per share = $590 mil + $150 mil convert debt = $740 mil mkt cap / $300 sales = 2.5 times 2023 sales with all 3 categories probably with CAGRs of > 10%-25%....that seems cheap with room to move up if mgt executes. We'll see what the next year+ brings.
  • R
    R
    *Heron Therapeutics Shares To Resume Trading At 3:15 P.M. EDT
  • E
    EyeSee
    Is it halted?
  • J
    Jack
    No reason to be short now ? Makes little sense for a sort position now once they slowly cover the downside is fairly limited so what is the point to be short any longer ?
  • H
    Hmmm
    That was an impressive amount of shares they had to throw at it in 45 minutes...9 mil shares to keep it down...market on close was also 9 mil shares (so was all that trading in the last 45 min all for the MOC?)

    We'll see what the short interest is for the end of Sept in another month. I highly doubt all the institutions that have been holding it this long all decided to sell on the news today.

    It'd be great if an Icahn or another activist decided to take a position today, not that we'd get that lucky, but it would make things interesting.

    Still don't understand why mgt doesn't step up and buy big with the stock at these levels. Maybe one of the analysts will ask on Monday why they don't.

    We'll see what happens on Monday...should be another interesting week.
  • R
    Ray
    Short shares are down to a 10 month low. And there have already been a few close calls that almost triggered a short squeeze. Since July outstanding short shares were over 40m. As of August 31st (last reported publicly) short shares were down to 32 million. That's a 20% decrease folks. That's a very good sign. Shorts know their position is not sustainable right now and that's why you're seeing desperate posts from several of them. Just call them a short so others can identify them when they post.
  • J
    Jeffrey
    Shouldn't we stop talking about shorts and start taking about the need for Zenrelef to ramp up quickly . It seems that based on the stock price after they just got approval for 019 the investment community just doesn't have a whole lot of confidence in substantial ramp up and revenues of anything heron does - I hope I am wrong
    There is no reason for a company with 4 approved drugs to be selling at 4 dollars plus - lots of companies with no revenues and less approved drugs are selling for alot more .
    I think shorting is turning into a long standing excuse .
  • F
    Ferran
    Remember the fact that they are losing 60 million every Qrt. and, they just have money for two Qrts., so big dilution is coming.
  • D
    Darth Barrister
    Now let's see how the action reverses. If you are short, I hope you closed some of your positions.
  • F
    FRANCIS
    With 32% SI, today shorts were selling like CRAZY by borrowing shares to keep the price down
    Mayhem to begin very soon on them, they can borrow only so much
    HOLD and not sell, put a sell limit of $20 after you buy so that your brokerage funds can't borrow your shares